Gallant Shark Tank Update

Gallant Shark Tank Pitch

Aaron Hirschhorn appeared on Shark Tank Season 11, Episode 8, which aired on November 16, 2019, with stem cell therapy for dogs.

Gallant is listed in the PetProducts category. In plain terms, the business is described as stem cell therapy for dogs.

Gallant asked the Sharks for $500,000 for 2%, implying a valuation of about $25 million.

On the show, Gallant made a listed deal with Lori Greiner for $500,000 for 5%.

If treated as straight equity, the listed deal works out to about $10 million implied valuation, down from the original $25 million implied valuation.

This pitch is included as context for the more important question: what happened after Shark Tank.

Gallant After Shark Tank

Gallant accepted an on-air offer, but follow-up reporting says the Shark Tank deal did not close. The company continued building around pet stem-cell banking and regenerative medicine rather than disappearing after due diligence. (Gallant Shark Tank update

Follow-up reporting placed the business around $2.5 million in annual revenue and later noted a $15 million Series A round in January 2024. Gallant also expanded beyond dogs with plans for cats and horses. (Gallant follow-up reporting

The current Gallant site is active and focuses on regenerative medicine for pets, including stem-cell banking and veterinary-facing therapies. The business is more medical-platform than simple consumer pet product at this point. (Gallant official site

Sources

Sources used for this page: Shark Tank API pitches